Duane Mitchell

Duane Mitchell, M.D.

Associate Chair And Professor

Department: MD-NEUROLOGICAL SURGERY
Business Phone: (352) 273-9000

About Duane Mitchell

Duane Anthony Mitchell, MD, PhD, is co-director of the Preston A. Wells Jr. Center for Brain Tumor Therapy and director of the UF Brain Tumor Immunotherapy Program. He is the Phyllis Kottler Friedman Professor for the Department of Neurosurgery and the State of Florida Endowed Cancer Research Chair at the UF College of Medicine.

Dr. Mitchell graduated from Rutgers College in New Brunswick, with a bachelor’s degree in biology before receiving his medical degree and doctorate degree in immunology from Duke University in Durham, in 2001. Dr. Mitchell conducted his postgraduate training in pathology and a neuro-oncology research at Duke University Medical Center prior to joining the faculty as an assistant professor. 

During his tenure at Duke, Dr. Mitchell held positions such as preclinical research at the Preston Robert Tisch Brain Tumor Center and associate director of the Duke Brain Tumor Immunotherapy Program. He also served as an active member of several institutional regulatory boards governing the conduct of human clinical trials.

In 2013, Dr. Mitchell joined the University of Florida faculty where he leads a comprehensive brain tumor program focused on translational research. This addition to the brain tumor program at UF was made possible by the Wells Foundation gift, combined with matching funds from other university sources, totaling $20 million dedicated to brain tumor treatment and research.

He has considerable clinical and translational research experience, having served as principal investigator on nine first-in-human protocols through FDA-approved clinical trials. The goal of these trials is to see improvements in patient outcomes using novel approaches that stimulate immune responses against malignant brain tumor cells in combination with current standard treatments. Dr. Mitchell’s research team will expand upon early successes observed in these personalized cancer treatment approaches and offer unique clinical options at UF Health for adult and pediatric patients diagnosed with malignant brain tumors.

Dr. Mitchell currently serves as a chartered member of the National Institutes of Health Study Section on Cancer Immunopathology and Immunotherapy, chair of the NCI Pediatric Brain Tumor Consortium Immunotherapy Committee, member of the NCI Brain Malignancy Steering Committee Immunotherapy Working Group, and gubernatorial appointee to the Florida Center for Brain Tumor Research Scientific Advisory Council. He has more than 50 refereed journal publications and 17 textbook chapters and scientific reviews and is inventor on eight filed United States patents on findings from his oncological research. Dr. Mitchell has been invited to serve on several scientific advisory 

Clinical Profile

Specialties
  • Neurosurgery

Publications

2019 Proceedings of the National Academy of Sciences of the United States of America. Biological Sciences
2019 Molecular Therapy : The Journal Of The American Society Of Gene Therapy
2019 Journal of Hematology & Oncology
2018 Current Treatment Options in Oncology
2018 International Journal of Molecular Sciences
2018 Journal of Clinical and Translational Science
2018 Current Treatment Options in Oncology
2017 Translational Immunotherapy of Brain Tumors
2016 Neuro-Oncology
2013 Journal for Immunotherapy of Cancer
2013 Experimental Neurology
2012 Handbook Of Clinical Neurology
2011 Brain Tumors: Current and Emerging Therapeutic Strategies
2011 Neuro-Oncology
2011 Journal of Clinical Oncology
2011 Future Oncology

Grants

December 2019 ACTIVE
A vaccine strategy to overcome treatment induced immunosuppression in glioma
AMER BRAIN TUMOR ASSOCIATION ·
September 2019 ACTIVE
Hematopoietic stem cells overcome treatment resistance to adoptive cellular therapy against malignant gliomas
NATL INST OF HLTH NINDS ·
August 2019 ACTIVE
Reprogramming Host Immunity in Treatment-Resistant Head and Neck Cancer Using Personalized RNA Nanoparticle Vaccines
TRIOLOGICAL SOCIETY ·
July 2019 ACTIVE
Immunotherapeutic targeting of osteosarcoma with nanoparticle vaccines
Rally Foundation ·
February 2019 ACTIVE
Rosen Foundation Funds
UF FOU · Principal Investigator
September 2018 ACTIVE
Targeting CCR2-expressing myeloid cells to overcome immune checkpoint inhibitor resistance in glioma
NATL INST OF HLTH NINDS ·
July 2018 – July 2019
Engineering a Clinically Accessible Biomarker for Glioblastoma Immunotherapy
CIRCLE OF HOPE FOR CANCER RES INC · Project Manager
July 2018 ACTIVE
Legacy Foundation
UF FOU · Principal Investigator
May 2018 ACTIVE
Engineering RNA-nanoparticles to enhance dendritic cell mediated treatment of glioblastoma
NATL INST OF HLTH NCI · Mentor
February 2018 – January 2019
Engineering a clinically accessible biomarker for glioblastoma immunotherapy
UF FOU · Principal Investigator
November 2017 ACTIVE
Selective Expansion of Neoantigen-Specific T Cells Targeting Medulloblastoma
THE V FOU FOR CANCER RESEARCH · Principal Investigator
September 2017 ACTIVE
RNA-nanoparticles targeting H3.3 K27M epitopes in diffuse intrinsic pontine glioma
US ARMY MED RES ACQUISITION ·
September 2017 ACTIVE
Immunologic Targeting of Developmentally-Regulated Antigens for the Treatment of High-Risk Medulloblastoma
NATL INST OF HLTH NCI · Mentor
July 2017 ACTIVE
Core Clinical Consortium for Blood and Marrow Transplant Clinical Trials Network
NATL INST OF HLTH NHLBI ·
July 2017 ACTIVE
Newly-Diagnosed Brain Stem Gliomas Treated with Adoptive Cellular Therapy During Recovery from Focal Radiotherapy Alone or Radiotherapy and Dose-intensified Temozolomide
THE LYLA NSOULI FOU CHILDRENS BRAIN CANC · Principal Investigator
July 2017 ACTIVE
Adoptive Cellular Therapy following Dose-Intensified Temozolomide in Newly-diagnosed Pediatric High-grade Gliomas (Phase I)
H LEE MOFFITT CANCER CTR · Principal Investigator
June 2017 ACTIVE
Newly-Diagnosed Brain Stem Gliomas Treated with Adoptive Cellular Therapy during Recovery from Focal Radiotherapy Alone or Radiotherapy and Dose-intensified Temozolomide
ACCELERATE BRAIN CANCER CURE · Principal Investigator
December 2016 ACTIVE
Leveraging Temozolomide to Improve Treatment Efficacy of Immune Checkpoint Blockade in Glioblastoma
NATL INST OF HLTH NINDS · Mentor
September 2016 ACTIVE
Harnessing the Immunologic Capacity of RNA-nanoparticle Vaccines Targeting Glioblastoma
NATL INST OF HLTH NCI · Mentor
July 2016 ACTIVE
NSU Immunomix GMP
UF FOU · Principal Investigator
April 2016 ACTIVE
A Safety and Preliminary Efficacy trial of MK-3475 (pembrolizumab; anti-PD-1) in Children with recurrent, progressive or refractory high-grade gliomas (HGG) and DIPGs
ST JUDE CHILDRENS RESEARCH HOSPITAL · Principal Investigator
April 2016 – March 2019
A Phase I Trial of Pomalidomide for children with recurrent, progressive or refractory CNS tumors
ST JUDE CHILDRENS RESEARCH HOSPITAL · Principal Investigator
January 2016 – January 2020
Immunologic targeting of molecular subtypes of medullobl
HYUNDAI HOPE ON WHEELS · Principal Investigator
September 2015 – August 2016
Establish comparative immunogenicity of LAMP modified pp
IMMUNOMIC THERAPEUTICS INC · Principal Investigator
August 2015 ACTIVE
Efficacy of Dendritic Cell Vaccines Targeting CMV in Glioblastoma (phase 2 DC vaccine)
NATL INST OF HLTH NCI · Principal Investigator
June 2015 ACTIVE
Enhancing Adoptive Immunotherapy Targeting Pediatric High-Grade Gliomas
NATL INST OF HLTH NCI · Principal Investigator
May 2015 – May 2017
Therapeutic Targeting of immune metabolism
UF DIV OF SPONSORED RESEARCH · Project Manager
April 2015 ACTIVE
Pediatric Brain Tumor Consortium
CHILDRENS RESEARCH INSTITUTE · Principal Investigator
December 2014 – May 2016
PCF – The Sunshine Project
H LEE MOFFITT CANCER CTR · Principal Investigator
January 2014 ACTIVE
B.R.E.T.
UF FOU · Principal Investigator
July 2013 ACTIVE
Florida Center for Brain Tumor Research – Statewide Brain Tumor Registry Program at the McKnight Brain Institute
FL DEPT OF HLTH · Project Manager
July 2013 – December 2019
Re-MATCH: Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor Adoptive Cell Therapy During Recovery from Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation
US ARMY MED RES ACQUISITION · Principal Investigator
July 2013 ACTIVE
Endowed Research Chair
UF HEALTH SHANDS HOSPITAL · Principal Investigator
July 2013 – June 2016
R01 transfer
NATL INST OF HLTH NINDS · Principal Investigator

Patents

Published January 2018
Hematopoietic Stem Cells in Combinatorial Therapy with Immune Checkpoint Inhibitors Against Cancer
#US-2018-0214544-A1

Contact Details

Phones:
Business:
(352) 273-9000